Triple-Drug attack on rare lymphoma shows early promise
NCT ID NCT03523975
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing whether a combination of three drugs—venetoclax, lenalidomide, and rituximab—is safe and effective for people with untreated mantle cell lymphoma, a rare blood cancer. About 28 adults will take these pills and infusions over several months. The goal is to find the best dose and see how many patients achieve complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, lenalidomide, and rituximab (drug combination)
What this could lead to
If successful, this could offer a new, effective first-line treatment option for mantle cell lymphoma, potentially improving remission rates.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it's not yet known if it works better than current standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact